AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.

Eligibility & Criteria

IRB #:
16-012888
Study Phase:
Phase II
Eligible Age Range:
Any
Study Categories: